Sugi Predict

Sugi Predict / Compounds / SCHEMBL458216

SCHEMBL458216

SCHEMBL458216

CS(=O)(=O)OCCC1CCN(C(=O)O)CC1

nearest known ligand 0.38

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 11/20 0.38
▸ TEAD1 P28347 1/20 0.38
▸ TEAD3 Q99594 1/20 0.38
▸ ALDH1A1 P00352 2/20 0.37
▸ ATM Q13315 1/20 0.37
▸ AKR1C3 P42330 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.35
▸ USP2 O75604 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ MMP9 P14780 1/20 0.35
▸ ALOX15 P16050 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ SCN9A Q15858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2126089 0.91 GPR119 (0.34) GPR119TEAD1TEAD3ALDH1A1ATM
SCHEMBL25288406 0.91 GPR119 (0.34) GPR119TEAD1TEAD3ALDH1A1ATM
SCHEMBL4438764 0.91 GPR119 (0.44) GPR119TEAD1TEAD3ALDH1A1ATM
SCHEMBL2126084 0.91 GPR119 (0.34) GPR119TEAD1TEAD3ALDH1A1ATM
SCHEMBL23387564 0.87 GPR119 (0.38) GPR119TEAD1TEAD3ALDH1A1ATM
SCHEMBL2369188 0.86 GPR119 (0.38) GPR119TEAD1TEAD3ALDH1A1ATM
SCHEMBL3533847 0.83 ALDH1A1 (0.35) GPR119ALDH1A1ATM
SCHEMBL21063450 0.83 KDM4E (0.38) ALDH1A1KDM4EUSP2LMNAMMP9
SCHEMBL310750 0.82 GPR119 (0.57) GPR119SCN9A
SCHEMBL3126252 0.82 FAAH (0.43) GPR119ALDH1A1ATMSCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239777-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-07-18 — — US disclosed
EP-3790871-B1 FURIN INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2024-01-24 — — EP disclosed
US-11807636-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-11-07 — — US disclosed
US-11773078-B2 Furin inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-10-03 — — US disclosed
US-20220315556-A1 FURIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2022-10-06 — — US disclosed
US-11352350-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2022-06-07 — — US disclosed
US-20210323952-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2021-10-21 — — US disclosed
EP-3886904-A1 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2021-10-06 — — EP disclosed
US-11117889-B1 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2021-09-14 — — US disclosed
EP-3558981-B1 PYRAN DERIVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS ORION CORP (FI) 2021-05-26 — — EP disclosed
WO-2009045382-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS MERCK & CO., INC. (US) 2009-04-09 — — WO disclosed
EP-2004615-A2 QUINAZOLINES FOR PDK1 INHIBITION Novartis AG (CH) 2008-12-24 — — EP disclosed
CN-100439344-C 4-Anilinoquinazoline derivatives as antiproliferative agents ASTRAZENECA AB (SE) 2008-12-03 — — CN disclosed
EP-1909791-A1 G-PROTEIN COUPLED RECEPTOR AGONISTS Prosidion Limited (GB) 2008-04-16 — — EP disclosed
WO-2007117607-A2 QUINAZOLINES FOR PDK1 INHIBITION NOVARTIS AG (CH) 2007-10-18 — — WO disclosed
CN-101003515-A 4-anilino quinazoline derivatives as antiproliferative agents ASTRAZENECA AB (SE) 2007-07-25 — — CN disclosed
WO-2007003964-A1 G-PROTEIN COUPLED RECEPTOR AGONISTS PROSIDION LIMITED (GB) 2007-01-11 — — WO disclosed
EP-1585515-A2 PIPERIDINE AND PYRROLIDINE DERIVATIVES AS ANTAGONISTS OF HISTAMINE H3 RECEPTOR NOVO NORDISK A/S (DK) 2005-10-19 — — EP disclosed
CN-1656081-A 4-Anilinoquinazoline derivatives as antiproliferative agents ASTRAZENECA AB (SE) 2005-08-17 — — CN disclosed
WO-2004054973-A2 PIPERIDINE AND PYRROLIDINE DERIVATIVES AS ANTAGONISTS OF HISTAMINE H3 RECEPTOR NOVO NORDISK A/S (DK) 2004-07-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220315556-A1 FURIN INHIBITORS FURIN, TGFB1, PCSK7 GPR119 2318/4885TEAD1 3178/4885TEAD3 3647/4885
US-11117889-B1 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 GPR119 2426/4885TEAD1 3177/4885TEAD3 3246/4885
US-11352350-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 GPR119 2426/4885TEAD1 3177/4885TEAD3 3246/4885
US-20210323952-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 GPR119 2426/4885TEAD1 3177/4885TEAD3 3246/4885
US-20240239777-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 GPR119 2426/4885TEAD1 3177/4885TEAD3 3246/4885
US-11807636-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 GPR119 2426/4885TEAD1 3177/4885TEAD3 3246/4885
US-11773078-B2 Furin inhibitors FURIN, TGFB1, PCSK7 GPR119 2318/4885TEAD1 3178/4885TEAD3 3647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.